Welcome to our dedicated page for Target Group SEC filings (Ticker: CBDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Target Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Target Group's regulatory disclosures and financial reporting.
Target Group Inc., a Canadian cannabis cultivator and processor listed on the Pink Limited Market under “CBDY,” reported 2025 revenue of $3.88 million, down from $6.59 million in 2024, and a net loss of $1.36 million after a small profit the prior year. The company had a working capital deficit of $11.05 million, an accumulated deficit of $32.31 million, and year-end cash of $100,410, while payables to related parties totaled $10.36 million. Its auditor issued a going concern warning, citing these deficits and liquidity pressures. Target operates primarily through its Canary Rx facility in Ontario, producing premium cannabis for Canada’s wholesale market, and faces industry headwinds, including regulatory complexity, oversupply, pricing pressure, and consolidation in the Canadian cannabis sector.
Target Group Inc. (CBDY) filed its Q3 2025 10‑Q, reporting softer sales and continued losses amid liquidity pressure. Q3 revenue was $499,650 versus $541,113 a year ago, with a net loss of $479,392 versus $528,950. For the nine months, revenue was $3,145,813 versus $4,736,055, and net loss was $807,375 versus $55,454.
The balance sheet shows cash of $337,488 and total assets of $6,197,102 against total liabilities of $13,630,641, resulting in a stockholders’ deficiency of $7,433,539. Current liabilities include $10,198,072 payable to related parties and $104,100 in deferred revenue.
Management disclosed “substantial doubt” about the company’s ability to continue as a going concern, citing a working capital deficit of $10,558,219 and an accumulated deficit of $31,754,219. Interest and bank charges were $781,452 year‑to‑date, reflecting a heavy financing burden. As of November 7, 2025, 617,025,999 common shares were outstanding.